RxDoctor Payments Data

York Sing Chan, DO

Internal Medicine · Brooklyn, NYNPI 1891010286

Payments from drug & device makers

$5,097in general payments, 2019–2025

Across 238 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Gilead$833
  • Lilly USA, LLC$457
  • Amgen$379
  • GSK$366
  • Amarin Pharma, Inc.$332
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$5,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,097 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$74,646
Medicare patients
166
Services billed
1,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Epolamine1,245$1,218,154
VascepaIcosapent Ethyl836$500,358
JardianceEmpagliflozin235$246,357
RybelsusSemaglutide108$221,842
Diclofenac Sodium803$180,016
FarxigaDapagliflozin Propanediol144$156,883
JanuviaSitagliptin Phosphate120$128,931
EliquisApixaban107$116,717
VemlidyTenofovir Alafenamide63$98,200
ProliaDenosumab57$97,181
Dupixent SyringeDupilumab20$76,459
Bepotastine Besilate341$70,044
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate50$68,369
JanumetSitagliptin Phos/Metformin Hcl56$63,087
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$58,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$19$276,681279 claims
Novo NordiskRybelsus, Ozempic$268$273,047153 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$1,076$195,973250 claims
PfizerEliquis$217$116,717107 claims
GileadVemlidy$833$98,20063 claims
AmgenProlia$379$97,18157 claims
AbbVieRestasis, Linzess, Synthroid$41$88,607216 claims
GSKTrelegy Ellipta$366$58,66781 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →